TY - JOUR
T1 - Autoimmune bullous skin diseases, pemphigus and pemphigoid
AU - Egami, Shohei
AU - Yamagami, Jun
AU - Amagai, Masayuki
N1 - Funding Information:
Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: J. Yamagami receives research support from the Kose Cosmetology Research Foundation. M. Amagai receives research support from Medical & Biological Laboratories, Ono Pharmaceutical, Japan Blood Products Organization, and RegCell. S. Egami declares no relevant conflict of interests. Z. K. Ballas (editor) disclosed no relevant financial relationships.
Funding Information:
M.A. receives research support from Health and Labor Sciences Research Grants for Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (grant no. 17933604 ) and Japan Agency for Medical Research and Development (grant no. 17824562 ). J.Y. receives research support from Grants-Aid for Scientific Research (grant no. 19111560 ).
Publisher Copyright:
© 2020 American Academy of Allergy, Asthma & Immunology
PY - 2020/4
Y1 - 2020/4
N2 - Autoimmune bullous skin diseases, such as pemphigus and pemphigoid, may enable clarification of the mechanisms of immune regulation in the skin. Pemphigus and pemphigoid are mediated by essentially IgG autoantibodies against structural proteins of the desmosomes at cell-cell junctions and hemidesmosomes at epidermal-dermal junctions, respectively, and are characterized by blisters and erosions in the skin and/or mucous membranes. Intensive investigation over the last 3 decades has identified their target antigens and developed serological diagnostic tools as well as mouse models to help us understand their pathophysiology. Based on these advances, several new therapeutic approaches have become available, and more effective and less toxic targeted approaches are under development.
AB - Autoimmune bullous skin diseases, such as pemphigus and pemphigoid, may enable clarification of the mechanisms of immune regulation in the skin. Pemphigus and pemphigoid are mediated by essentially IgG autoantibodies against structural proteins of the desmosomes at cell-cell junctions and hemidesmosomes at epidermal-dermal junctions, respectively, and are characterized by blisters and erosions in the skin and/or mucous membranes. Intensive investigation over the last 3 decades has identified their target antigens and developed serological diagnostic tools as well as mouse models to help us understand their pathophysiology. Based on these advances, several new therapeutic approaches have become available, and more effective and less toxic targeted approaches are under development.
KW - Autoimmune bullous diseases
KW - BP180
KW - ELISA
KW - desmoglein
KW - rituximab
KW - type XVII collagen BP230
UR - http://www.scopus.com/inward/record.url?scp=85082649756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082649756&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2020.02.013
DO - 10.1016/j.jaci.2020.02.013
M3 - Review article
C2 - 32272980
AN - SCOPUS:85082649756
VL - 145
SP - 1031
EP - 1047
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 4
ER -